文献速递胸部肿瘤

回顾与展望:非小细胞肺癌的「治愈」是否在改善?

Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer?
PubMed 文献 · Eur J Cancer · 2017-02-23

本文回顾非小细胞肺癌治愈率的改善历程,指出早期诊断通过经济有效的筛查项目受到关注,靶向治疗(EGFR突变、ALK重排)和免疫治疗使部分患者5年生存率显著提高,5年生存可能成为更重要终点。

要点

  • 手术系列中5年无癌生存常被视为治愈,近年改善治愈率的尝试聚焦于经济有效的筛查项目实现早期诊断。
  • EGFR突变和ALK重排等可靶向敏感突变患者预后显著更好,许多可生存超过5年。
  • 免疫治疗在选定NSCLC患者中有效,将使5年生存率再次跃升,5年生存可能成为更重要终点。

核心结论

  • 靶向治疗和免疫治疗使部分NSCLC患者5年生存率提高,5年生存可能成为更重要终点。

研究设计与样本

  • 本文为综述,回顾非小细胞肺癌治愈率改善的相关进展。

主要发现

  • 手术系列中5年无癌生存常被称为治愈。
  • 全身治疗在辅助和姑息治疗中历来仅小幅增加总生存。
  • 近二十年新治疗选择使NSCLC生存率逐步改善。
  • EGFR突变和ALK重排等可靶向敏感突变患者预后显著更好,许多可生存超过5年。
  • 免疫治疗在选定NSCLC患者中有效,将使5年生存率再次跃升。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In surgical series, cancer-free survival at 5 years is often referred to as a cure. In recent years, attempts to improve cure rates in non-small cell lung cancer (NSCLC) have focussed on earlier diagnosis through cost-effective screening programs. Systemic therapies have historically added only a small benefit to overall survival in both the adjuvant and palliative setting. However, in the last two decades, the development of new treatment options has added incremental improvements in NSCLC survival rates. Patients with a targetable sensitising mutation including epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase rearrangements have significantly better prognosis, and many will survive beyond 5 years. Immunotherapy is an effective treatment in selected patients with NSCLC and is set to cause another leap in 5 year survival rates. Although these patients are not free from disease, survival at 5 years may become the more important end-point as NSCLC becomes seen as a chronic oncological disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Walder D, O'Brien M. Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer? Eur J Cancer. 2017. PMID: 28236771. doi:10.1016/j.ejca.2017.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。